Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response

Two patients with rare fusion G13:A20 which were found in Chinese population by next generation sequencing (NGS) developed resistant to crizotinib with a prolonged progression-free survival (PFS). Both patients showed unfavorable response to subsequent second or third generation tyrosine kinase inhi...

Full description

Saved in:
Bibliographic Details
Published in:Translational cancer research 2019-09, Vol.8 (5), p.2187-2191
Main Authors: Qin, Jing, Zeng, Daxiong, Xie, Fajun, Yu, Ruoying, Wu, Xue, Liu, Kaihua, Shao, Yang W, Lu, Hongyang, Jiang, Junhong
Format: Article
Language:English
Subjects:
Brief Report
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two patients with rare fusion G13:A20 which were found in Chinese population by next generation sequencing (NGS) developed resistant to crizotinib with a prolonged progression-free survival (PFS). Both patients showed unfavorable response to subsequent second or third generation tyrosine kinase inhibitors (TKIs) treatment with shorten PFS. In conclusion, non-small cell lung cancer (NSCLC) patients with rare fusion G13:A20 may be optimal candidates for crizotinib as front-line therapy and may have a high possibility to exhibit unsatisfactory response to subsequent second or third generation TKIs target therapy after acquiring resistance to crizotinib.
ISSN:2218-676X
2219-6803
DOI:10.21037/tcr.2019.08.26